{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:55:27Z","timestamp":1791597327017,"version":"4.3.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T00:00:00Z","timestamp":1565308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WI3868\/1-1"],"award-info":[{"award-number":["WI3868\/1-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["WI3868\/4-1"],"award-info":[{"award-number":["WI3868\/4-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The serine protease hepsin is frequently overexpressed in human prostate cancer (PCa) and is associated with matrix degradation and PCa progression in mice. Curiously, low expression of hepsin is associated with poor survival in different cancer types, and transgenic overexpression of hepsin leads to loss of viability in various cancer cell lines. Here, by comparing isogenic transfectants of the PCa cell line PC-3 providing inducible overexpression of wild-type hepsin (HPN) vs. the protease-deficient mutant HPN<jats:sup>S353A<\/jats:sup>, we were able to attribute hepsin-mediated tumor-adverse effects to its excess proteolytic activity. A stem-like expression signature of surface markers and adhesion molecules, Notch intracellular domain release, and increased pericellular protease activity were associated with low expression levels of wild-type hepsin, but were partially lost in response to overexpression. Instead, overexpression of wild-type hepsin, but not of HPN<jats:sup>S353A<\/jats:sup>, induced relocalization of the protein to the cytoplasm, and increased autophagic flux in vitro as well as LC3B punctae frequency in tumor xenografts. Confocal microscopy revealed colocalization of wild-type hepsin with both LC3B punctae as well as with the autophagy cargo receptor p62\/SQSTM1. Overexpression of wild type, but not protease-deficient hepsin induced expression and nuclear presence of CHOP, indicating activation of the unfolded protein response and ER-associated protein degradation (ERAD). Whereas inhibitors of ER stress and secretory protein trafficking slightly increased viability, combined inhibition of the ubiquitin-proteasome degradation pathway (by bortezomib) with either ER stress (by salubrinal) or autophagy (by bafilomycin A1) revealed a significant decrease of viability during overexpression of wild-type hepsin in PC-3 cells. Our results demonstrate that a precise control of Hepsin proteolytic activity is critical for PCa cell fate and suggest, that the interference with ERAD could be a promising therapeutic option, leading to induction of proteotoxicity in hepsin-overexpressing tumors.<\/jats:p>","DOI":"10.1038\/s41419-019-1830-8","type":"journal-article","created":{"date-parts":[[2019,8,9]],"date-time":"2019-08-09T07:03:13Z","timestamp":1565334193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells"],"prefix":"10.1038","volume":"10","author":[{"given":"Ramona","family":"Willbold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"S\u00fcltmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-9370","authenticated-orcid":false,"given":"Rainer","family":"Wittig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,9]]},"reference":[{"key":"1830_CR1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.ju.0000101622.74236.94","volume":"171","author":"C Stephan","year":"2004","unstructured":"Stephan, C. et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J. Urol. 171, 187\u2013191 (2004).","journal-title":"J. Urol."},{"key":"1830_CR2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2004.07.008","volume":"6","author":"O Klezovitch","year":"2004","unstructured":"Klezovitch, O. et al. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 6, 185\u2013195 (2004).","journal-title":"Cancer Cell"},{"key":"1830_CR3","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/S0969-2126(03)00148-5","volume":"11","author":"JR Somoza","year":"2003","unstructured":"Somoza, J. R. et al. The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain. Structure 11, 1123\u20131131 (2003).","journal-title":"Structure"},{"key":"1830_CR4","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1073\/pnas.90.15.7181","volume":"90","author":"A Torres-Rosado","year":"1993","unstructured":"Torres-Rosado, A., O\u2019Shea, K. S., Tsuji, A., Chou, S. H. & Kurachi, K. Hepsin, a putative cell-surface serine protease, is required for mammalian cell growth. Proc. Natl Acad. Sci. USA 90, 7181\u20137185 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1830_CR5","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/ijc.23726","volume":"123","author":"J Miao","year":"2008","unstructured":"Miao, J. et al. Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. Int. J. Cancer 123, 2041\u20132047 (2008).","journal-title":"Int. J. Cancer"},{"key":"1830_CR6","doi-asserted-by":"crossref","first-page":"E388","DOI":"10.1073\/pnas.1120421109","volume":"109","author":"JI Partanen","year":"2012","unstructured":"Partanen, J. I. et al. Tumor suppressor function of Liver kinase B1 (Lkb1) is linked to regulation of epithelial integrity. Proc. Natl Acad. Sci. USA 109, E388\u2013E397 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1830_CR7","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1038\/onc.2015.248","volume":"35","author":"TA Tervonen","year":"2016","unstructured":"Tervonen, T. A. et al. Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF\/MET signalling and disrupting epithelial cohesion. Oncogene 35, 1832\u20131846 (2016).","journal-title":"Oncogene"},{"key":"1830_CR8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1042\/BJ20100046","volume":"428","author":"TM Antalis","year":"2010","unstructured":"Antalis, T. M., Buzza, M. S., Hodge, K. M., Hooper, J. D. & Netzel-Arnett, S. The cutting edge: membrane-anchored serine protease activities in the pericellular microenvironment. Biochem. J. 428, 325\u2013346 (2010).","journal-title":"Biochem. J."},{"key":"1830_CR9","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/13543784.2011.631523","volume":"20","author":"A Varkaris","year":"2011","unstructured":"Varkaris, A. et al. The role of HGF\/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin. Investig. Drugs 20, 1677\u20131684 (2011).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"1830_CR10","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/med.21308","volume":"34","author":"AH Mekkawy","year":"2014","unstructured":"Mekkawy, A. H., Pourgholami, M. H. & Morris, D. L. Involvement of urokinase-type plasminogen activator system in cancer: an overview. Med. Res. Rev. 34, 918\u2013956 (2014).","journal-title":"Med. Res. Rev."},{"key":"1830_CR11","first-page":"6812","volume":"62","author":"V Srikantan","year":"2002","unstructured":"Srikantan, V., Valladares., M., Rhim, J. S., Moul, J. W. & Srivastava, S. HEPSIN inhibits cell growth\/invasion in prostate cancer cells. Cancer Res. 62, 6812\u20136816 (2002).","journal-title":"Cancer Res."},{"key":"1830_CR12","first-page":"389","volume":"22","author":"K Nakamura","year":"2008","unstructured":"Nakamura, K. et al. Hepsin inhibits the cell growth of endometrial cancer. Int. J. Mol. Med. 22, 389\u2013397 (2008).","journal-title":"Int. J. Mol. Med."},{"key":"1830_CR13","first-page":"393","volume":"28","author":"K Nakamura","year":"2006","unstructured":"Nakamura, K. et al. Hepsin shows inhibitory effects through apoptotic pathway on ovarian cancer cell lines. Int. J. Oncol. 28, 393\u2013398 (2006).","journal-title":"Int. J. Oncol."},{"key":"1830_CR14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35090585","volume":"412","author":"SM Dhanasekaran","year":"2001","unstructured":"Dhanasekaran, S. M. et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822\u2013826 (2001).","journal-title":"Nature"},{"key":"1830_CR15","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1440-5","volume":"15","author":"M Pelkonen","year":"2015","unstructured":"Pelkonen, M. et al. Low expression levels of hepsin and TMPRSS3 are associated with poor breast cancer survival. BMC Cancer 15, 431 (2015).","journal-title":"BMC Cancer"},{"key":"1830_CR16","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1097\/01.ju.0000144602.01322.49","volume":"172","author":"A Roemer","year":"2004","unstructured":"Roemer, A. et al. The membrane proteases ADAMS and HEPSIN are differentially expressed in renal cell carcinoma. Are they potential tumor markers? J. Urol. 172, 2162\u20132166 (2004).","journal-title":"J. Urol."},{"key":"1830_CR17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1478-3231.2006.01307.x","volume":"26","author":"CH Chen","year":"2006","unstructured":"Chen, C. H. et al. Decreased expressions of hepsin in human hepatocellular carcinomas. Liver Int. 26, 774\u2013780 (2006).","journal-title":"Liver Int."},{"key":"1830_CR18","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.4161\/cc.3.11.1273","volume":"3","author":"V Vasioukhin","year":"2004","unstructured":"Vasioukhin, V. Hepsin paradox reveals unexpected complexity of metastatic process. Cell Cycle 3, 1394\u20131397 (2004).","journal-title":"Cell Cycle"},{"key":"1830_CR19","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1593\/neo.11294","volume":"13","author":"SM Wittig-Blaich","year":"2011","unstructured":"Wittig-Blaich, S. M. et al. Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. Neoplasia 13, 579\u2013589 (2011).","journal-title":"Neoplasia"},{"key":"1830_CR20","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1021\/cr000033x","volume":"102","author":"L Hedstrom","year":"2002","unstructured":"Hedstrom, L. Serine Protease Mechanism and Specificity. Chem. Rev. 102, 4501\u20134524 (2002).","journal-title":"Chem. Rev."},{"key":"1830_CR21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ijc.27675","volume":"132","author":"F Castro","year":"2013","unstructured":"Castro, F. et al. High-throughput SNP-based authentication of human cell lines. Int. J. Cancer 132, 308\u2013314 (2013).","journal-title":"Int. J. Cancer"},{"key":"1830_CR22","doi-asserted-by":"crossref","first-page":"23760","DOI":"10.18632\/oncotarget.15863","volume":"8","author":"S Wittig-Blaich","year":"2017","unstructured":"Wittig-Blaich, S. et al. Systematic screening of isogenic cancer cells identifies DUSP6 as context-specific synthetic lethal target in melanoma. Oncotarget 8, 23760\u201323774 (2017).","journal-title":"Oncotarget"},{"key":"1830_CR23","doi-asserted-by":"crossref","first-page":"6434","DOI":"10.1038\/onc.2008.310","volume":"27","author":"P Boya","year":"2008","unstructured":"Boya, P. & Kroemer, G. Lysosomal membrane permeabilization in cell death. Oncogene 27, 6434\u20136451 (2008).","journal-title":"Oncogene"},{"key":"1830_CR24","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1158\/1535-7163.MCT-06-0520","volume":"6","author":"M Zhu","year":"2007","unstructured":"Zhu, M. et al. Identification of a novel inhibitor of urokinase-type plasminogen activator. Mol. Cancer Ther. 6, 1348\u20131356 (2007).","journal-title":"Mol. Cancer Ther."},{"key":"1830_CR25","doi-asserted-by":"crossref","first-page":"31315","DOI":"10.1074\/jbc.272.50.31315","volume":"272","author":"TK Vu","year":"1997","unstructured":"Vu, T. K., Liu, R. W., Haaksma, C. J., Tomasek, J. J. & Howard, E. W. Identification and cloning of the membrane-associated serine protease, hepsin, from mouse preimplantation embryos. J. Biol. Chem. 272, 31315\u201331320 (1997).","journal-title":"J. Biol. Chem."},{"key":"1830_CR26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1042\/BJ20091448","volume":"426","author":"KA Owen","year":"2010","unstructured":"Owen, K. A. et al. Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem. J. 426, 219\u2013228 (2010).","journal-title":"Biochem. J."},{"key":"1830_CR27","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrm2821","volume":"11","author":"HW Smith","year":"2010","unstructured":"Smith, H. W. & Marshall, C. J. Regulation of cell signalling by uPAR. Nat. Rev. Mol. Cell. Biol. 11, 23\u201336 (2010).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"1830_CR28","doi-asserted-by":"crossref","first-page":"30439","DOI":"10.1074\/jbc.M605440200","volume":"281","author":"P Moran","year":"2006","unstructured":"Moran, P. et al. Pro-urokinase-type plasminogen activator is a substrate for hepsin. J. Biol. Chem. 281, 30439\u201330446 (2006).","journal-title":"J. Biol. Chem."},{"key":"1830_CR29","volume":"6","author":"GJLH van Leenders","year":"2011","unstructured":"van Leenders, G. J. L. H. et al. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One 6, e26753 (2011).","journal-title":"PLoS One"},{"key":"1830_CR30","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.febslet.2005.01.085","volume":"579","author":"D Kirchhofer","year":"2005","unstructured":"Kirchhofer, D. et al. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2. FEBS Lett. 579, 1945\u20131950 (2005).","journal-title":"FEBS Lett."},{"key":"1830_CR31","volume":"12","author":"Y Dai","year":"2012","unstructured":"Dai, Y. & Siemann, D. W. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 12, 198 (2012).","journal-title":"BMC Cancer"},{"key":"1830_CR32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/pros.10217","volume":"55","author":"N Clegg","year":"2003","unstructured":"Clegg, N. et al. Molecular characterization of prostatic small-cell neuroendocrine carcinoma. Prostate 55, 55\u201364 (2003).","journal-title":"Prostate"},{"key":"1830_CR33","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1034\/j.1600-0560.2003.00073.x","volume":"30","author":"M Deichmann.","year":"2003","unstructured":"Deichmann., M., Kurzen, H., Egner, U., Altevogt, P. & Hartschuh, W. Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). J. Cutan. Pathol. 30, 363\u2013368 (2003).","journal-title":"J. Cutan. Pathol."},{"key":"1830_CR34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pros.10324","volume":"58","author":"G Kristiansen","year":"2004","unstructured":"Kristiansen, G. et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58, 183\u2013192 (2004).","journal-title":"Prostate"},{"key":"1830_CR35","first-page":"439","volume":"61","author":"S Paglin","year":"2001","unstructured":"Paglin, S. et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 61, 439\u2013444 (2001).","journal-title":"Cancer Res."},{"key":"1830_CR36","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","volume":"140","author":"N Mizushima","year":"2010","unstructured":"Mizushima, N., Yoshimori, T. & Levine, B. Methods in mammalian autophagy research. Cell 140, 313\u2013326 (2010).","journal-title":"Cell"},{"key":"1830_CR37","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1080\/15548627.2015.1091141","volume":"11","author":"HO Rashid","year":"2015","unstructured":"Rashid, H. O., Yadav, R. K., Kim, H. R. & Chae, H. J. ER stress: autophagy induction, inhibition and selection. Autophagy 11, 1956\u20131977 (2015).","journal-title":"Autophagy"},{"key":"1830_CR38","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.devcel.2007.07.005","volume":"13","author":"J Wu","year":"2007","unstructured":"Wu, J. et al. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev. Cell 13, 351\u2013364 (2007).","journal-title":"Dev. Cell"},{"key":"1830_CR39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.devcel.2007.07.018","volume":"13","author":"K Yamamoto","year":"2007","unstructured":"Yamamoto, K. et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev. Cell 13, 365\u2013376 (2007).","journal-title":"Dev. Cell"},{"key":"1830_CR40","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1111\/febs.13598","volume":"283","author":"R Iurlaro","year":"2016","unstructured":"Iurlaro, R. & Mu\u00f1oz-Pinedo, C. Cell death induced by endoplasmic reticulum stress. FEBS J. 283, 2640\u20132652 (2016).","journal-title":"FEBS J."},{"key":"1830_CR41","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.bbamem.2010.06.015","volume":"1808","author":"R Zimmermann","year":"2011","unstructured":"Zimmermann, R., Eyrisch, S., Ahmad, M. & Helms, V. Protein translocation across the ER membrane. Biochim. Biophys. Acta Biomembr. 1808, 912\u2013924 (2011).","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"1830_CR42","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1242\/jcs.054494","volume":"122","author":"BCS Cross","year":"2009","unstructured":"Cross, B. C. S. et al. Eeyarestatin I inhibits Sec61-mediated protein translocation at the endoplasmic reticulum. J. Cell Sci. 122, 4393\u20134400 (2009).","journal-title":"J. Cell Sci."},{"key":"1830_CR43","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1126\/science.1101902","volume":"307","author":"M Boyce","year":"2005","unstructured":"Boyce, M. et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 307, 935\u2013939 (2005).","journal-title":"Science"},{"key":"1830_CR44","first-page":"47","volume":"5","author":"A Br\u00fcning","year":"2015","unstructured":"Br\u00fcning, A. & J\u00fcckstock, J. Misfolded proteins: from little villains to little helpers in the fight against. Cancer Front. Oncol. 5, 47 (2015).","journal-title":"Cancer Front. Oncol."},{"key":"1830_CR45","first-page":"4427","volume":"62","author":"DR Rhodes","year":"2002","unstructured":"Rhodes, D. R., Barrette, T. R., Rubin, M. A., Ghosh, D. & Chinnaiyan, A. M. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res. 62, 4427\u20134433 (2002).","journal-title":"Cancer Res."},{"key":"1830_CR46","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2310\/JIM.0b013e31821451a1","volume":"59","author":"P Xing","year":"2011","unstructured":"Xing, P. et al. Clinical and biological significance of hepsin overexpression in breast cancer. J. Investig. Med. 59, 803\u2013810 (2011).","journal-title":"J. Investig. Med."},{"key":"1830_CR47","first-page":"2884","volume":"57","author":"H Tanimoto","year":"1997","unstructured":"Tanimoto, H. et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res. 57, 2884\u20132887 (1997).","journal-title":"Cancer Res."},{"key":"1830_CR48","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s11658-016-0031-z","volume":"21","author":"WJ Liu","year":"2016","unstructured":"Liu, W. J. et al. p62 links the autophagy pathway and the ubiqutin-proteasome system upon ubiquitinated protein degradation. Cell. Mol. Biol. Lett. 21, 29 (2016).","journal-title":"Cell. Mol. Biol. Lett."},{"key":"1830_CR49","doi-asserted-by":"crossref","first-page":"20130111","DOI":"10.1098\/rstb.2013.0111","volume":"368","author":"JI Partanen","year":"2013","unstructured":"Partanen, J. I., Tervonen, T. A. & Klefstr\u00f6m, J. Breaking the epithelial polarity barrier in cancer: the strange case of LKB1\/PAR-4. Philos. Trans. R. Soc. Lond. B Biol. Sci. 368, 20130111 (2013).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"1830_CR50","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2018.09.021","volume":"438","author":"C Zhang","year":"2018","unstructured":"Zhang, C., Zhang, M. & Song, S. Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation. Cancer Lett. 438, 105\u2013115 (2018).","journal-title":"Cancer Lett."},{"key":"1830_CR51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.05.003","volume":"127","author":"M Wang","year":"2018","unstructured":"Wang, M., Law, M. E., Castellano, R. K. & Law, B. K. The unfolded protein response as a target for anticancer therapeutics. Crit. Rev. Oncol. Hematol. 127, 66\u201379 (2018).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"1830_CR52","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/15548627.2016.1191722","volume":"12","author":"X Li","year":"2016","unstructured":"Li, X. et al. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Autophagy 12, 1521\u20131537 (2016).","journal-title":"Autophagy"},{"key":"1830_CR53","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1158\/0008-5472.CAN-08-3858","volume":"69","author":"DM Schewe","year":"2009","unstructured":"Schewe, D. M. & Aguirre-Ghiso, J. A. Inhibition of eIF2alpha dephosphorylation maximizes bortezomib efficiency and eliminates quiescent multiple myeloma cells surviving proteasome inhibitor therapy. Cancer Res. 69, 1545\u20131552 (2009).","journal-title":"Cancer Res."},{"key":"1830_CR54","volume":"4","author":"HCA Drexler","year":"2009","unstructured":"Drexler, H. C. A. Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors. PLoS One 4, e4161 (2009).","journal-title":"PLoS One"},{"key":"1830_CR55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/toxsci\/kfy238","volume":"167","author":"MM Hossain","year":"2019","unstructured":"Hossain, M. M., Sivaram, G. & Richardson, J. R. Regional Susceptibility to ER stress and protection by salubrinal following a single exposure to deltamethrin. Toxicol. Sci. 167, 249\u2013257 (2019).","journal-title":"Toxicol. Sci."},{"key":"1830_CR56","volume":"11","author":"J Wen","year":"2016","unstructured":"Wen, J., Jiang, Y., Zhang, C., Chen, S. & Li, H. The protective effects of salubrinal on the cartilage and subchondral bone of the temporomandibular joint under various compressive mechanical stimulations. PLoS ONE 11, e0155514 (2016).","journal-title":"PLoS ONE"}],"updated-by":[{"DOI":"10.1038\/s41419-020-2321-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000}}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1830-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1830-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1830-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:27:11Z","timestamp":1671211631000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-1830-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,9]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["1830"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-1830-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41419-020-2321-7","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,9]]},"assertion":[{"value":"7 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2020","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"601"}}